Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of ketoconazole, a synthetic imidazole derivate, were evaluated in 42 women affected by acne (17 cases) and/or hirsutism (36 cases) treated with 400 mg/day for 3-6 months. Androstenedione, total and free testosterone, 5 alpha dihydrotestosterone and dehydroepiandrosterone levels progressively dropped during treatment while 17 alpha hydroxyprogesterone, estradiol, ACTH, cortisol, LH and FSH levels increased. Dehydroepiandrosterone sulfate decreased only towards the end of treatment, while estrone, sex hormone binding globulin, and PRL remained unchanged. Daily mean +/- SD rate of hair growth, measured by a special image analysis processor, decreased within 3 months of therapy from 0.258 +/- 0.058 to 0.184 +/- 0.039 mm/day (P less than 0.02) and mean +/- SD hair diameter from 0.123 +/- 0.015 to 0.110 +/- 0.013 mm (P less than 0.05) together with decreasing hormone levels. The therapeutic effects of ketoconazole on hirsutism was evident at 6 months in only 14 subjects, while no significant change in hirsutism score was recorded in 22 women who failed to complete the therapy. Acne improved in all cases. Several side effects and complications arose during treatment, such as headache, nausea, loss of scalp hair, hepatitis, and biochemical changes. Even though ketoconazole improves hyperandrogenism, only selected patients are eligible for treatment as scrupulous monitoring is required.
 ...
PMID:Ketoconazole therapy for women with acne and/or hirsutism. 216 69

We performed phase I study of FK 435, a new antiestrogen, in 30 patients with advanced breast cancer. Slight to moderate adverse reactions were noted as follows. Single-dose study: anorexia, nausea, lassitude in one patient (80 mg), decreased serum calcium in one (160 mg), redness, tenderness in one, facial flushing, hot flushes, headache in one (320 mg). Repeated-dose study: anorexia, nausea in one patient (40 mg/day), anorexia, diarrhea, increased FSH in one, increased PRL in one (80 mg/day). FK 435 was well tolerated. Tmax was 3-5 hours, T1/2 about 25 hours. Most of FK 435 was excreted into urine as glucuronide.
 ...
PMID:[Phase I study of FK 435]. 219 79

A 17 year-old boy was admitted to the hospital because of thirst, polyuria (5-61/day), delayed sexual development and muscle weakness. He appeared obese, had an eunuchoidal body habitus and was excessively tall. Chromosomal analysis revealed a 47XXY karyotype. Serum cortisol was 1.3 microgram/dl, LH, 10.4 mIU/ml, FSH, 2.0 mIU/ml, and testosterone, 10 ng/dl. Endocrinological dynamic tests indicated diabetes insipidus and hypopituitarism of a hypothalamic type. Brain CT disclosed the existence of a tumor shadow around the calcified pineal body, extending towards the suprasellar region. Replacement therapy with glucocorticoid and DDAVP was started. The patient complained of a headache and plasma AFP and hCG concentrations were 868 ng/ml and 68.6 IU/ml respectively. A hCG- and AFP- producing germ cell tumor was suspected and radiation therapy with 60Co was performed. Plasma AFP and hCG were decreased with significant clinical improvement. Soon after irradiation, he started to complain of a headache and had elevated AFP and hCG levels. Right hemiparesis and unconsciousness suddenly appeared and he died of left thalamic bleeding. This is the first case of Klinefelter's syndrome associated with intracranial germ cell tumor. Plasma testosterone levels fluctuated in parallel with the change in plasma hCG levels. This shows that the Leydig cells in this patient could respond to some extent to tumor-producing hCG.
 ...
PMID:A case of Klinefelter's syndrome associated with hypothalamic-pituitary dysfunction caused by an intracranial germ cell tumor. 244 Jun 66

Contraceptive implants containing progestin have been marketed in Finland since 1984. The method utilizes 6 silicon capsules of 36 mg levonorgestrel that are implanted inside the upper arm under local anesthesia. Each capsule is 34 mm long and 2.5 mm wide. The capsules release 100 mcg levonorgestrel a day during the 1st 3 months, after which dosage decreases to a level of 30-35 mcg a day within 15 months. The rate of release remains the same for a period of up to 6.5 years. Some users experience no ovulation or an incomplete luteal phase. The level of estradiol varies, although FSH, LH and androgen levels do no essentially change. Cholesterol ratios remain unchanged, but the levels decrease somewhat. Blood coagulation problems due to menstrual problems, primarily frequent, irregular bleeding and spotting. Side effects such as headaches, weight gain, mood changes can be caused by the capsule, as well as the contraceptive pill. During implantation and removal there is a small (0.3) risk of infection. Teratogenic and mutagenic effects are unlikely. Studies have shown no pregnancies occurring in the 1st 2 years of use. The 3rd year, the cumulative rate has been shown to be 0.3, and for the 4th year 0.7. To a great extent, contraceptive implants are utilized by women who have had bad experiences with other methods, and who already have the desired number of children. This method offers much promise to those women in developing countries, and has been proven to be well tolerated there.
 ...
PMID:[Subcutaneous hormone capsules]. 333 Nov 42

A trial of a triphasic oral contraceptive in 13 women with polycystic- ovary syndrome is presented, backed up with data on levels of sex hormone binding globulin (SHBG), testosterone, androstenedione, 17-OH-progesterone and other hormones. This illness is really a hyperandrogenic response of the ovary secondary to high gonadotropin levels and unopposed estrogens with low SHBG. Only mediocre results have been reported with low-dose oral contraceptive treatment, compared to earlier high-dose pills. The pills used here contained 50 mcg levonorgestrel (LNG) with 30 mcg ethinyl estradiol (EE) for 6 days, 75 mcg LNG and 40 mcg EE for 5 days, and 125 mcg LNG with 30 mcg EE for 10 days. After 3 months of treatment LH levels fell from 29.7 to 3.6 mIU/m1; FSH fell from 12.3 to 2.6 mIU/m1, and the LH/FSH ratio decreased from 2.34 to 1.38. All androgens declined significantly (p0.01), into the normal range. Serum cortisol rose significantly from 16.9-36.7 mcg/100 ml. SHBG rose from 1.67-3.0 mcg/100 ml, the high limit of normal. Hirsutism and acne improved in all but 1 patient. 1 woman dropped out because of weight gain, and another because of nausea and headache. These results suggest that triphasic oral contraceptives may be safe and effective for chronic anovulatory syndrome.
 ...
PMID:SHBG, testosterone, androstenedione, 17-OH-Progesterone plasma levels in PCO affected women treated with a triphasic oral contraceptive. 345 1

In 103 sexually mature women with disturbance of ovulation, a possible relationship between Kupperman menopausal complaints and endocrinological status was investigated to find the cause of climacteric syndrome. The Kupperman index was increased as the disturbance of ovulation was advanced from the stage of anovulatory cycle to amenorrhea I and further to amenorrhea II. In parallel with the advance in disturbance of ovulation, serum FSH and LH levels rose significantly, and serum estrone (E1) and estradiol (E2) levels dropped. Prolactin (PRL) showed a tendency to decrease. There were some hormonal patterns characteristic of individual complaints; hot flush was associated with increased FSH and LH, and decreased E1 and E2; difficulty in falling asleep, excitability, and fatigability, with increased FSH and LH, and decreased E2; nervousness, with increased LH and decreased E2; headache, with increased LH and PRL, and decreased E2; feeling of cold, with decreased E2 and PRL; and numbness and shoulder stiffness, with decreased E2. In sexually mature women, the complaints associated with abnormal levels of two or more kinds of hormones seemed to be most specifically related with decreased E2, followed by increased LH. Fatigability and headache developed specifically in the ovulatory phase of women with normal menstrual cycles (105 subjects), suggesting that these two complaints are closely related to increased LH. These results indicate that the majority of Kupperman menopausal complaints have their individually specific endocrinological cause, and that they may develop even in sexually mature women if those specific conditions exist. In climacteric syndrome in a narrow sense (i.e., dysautonomic type), each complaint may also have its specific endocrinological cause.
 ...
PMID:[Serum hormone level and Kupperman menopausal complaints in sexually mature women with disturbance of ovulation]. 391 22

A 34-year-old male with a pituitary adenoma was investigated and demonstrated to have hypersecretion of both gonadotrophins in the basal state. Immunocytochemical staining and electron microscopic examination were positive for tumour cells secreting FSH and LH. Presenting symptoms included visual disturbances, loss of libido, impotence, cold intolerance, frontal headaches, change in skin pigmentation and excessive weight gain. The patient denied alteration in hair distribution, had no acral features, galactorrhoea or gynaecomastia. Surgical extirpation resulted in complete amelioration of his symptoms over a three year follow-up period. Basal and stimulated pituitary function testing results returned to normal post-operatively. A review of the literature documents six other cases of pituitary tumour secreting both LH and FSH in the basal state. More commonly, the pituitary adenoma secretes FSH only. The literature is reviewed with regard to both types of tumour.
 ...
PMID:Gonadotrophin-secreting pituitary tumour: report and review. 391 72

Experience with a small dose of d-Norgestrel as an oral contraceptive in 60 patients is reported. 336 cycles were observed. 2 pregnancies occurred, after 1 month and 9 months treatment; in both cases the patients had not taken the medication regularly. Side effects included spotting (50%), menstrual cycle irregularity (40%), headache, increased appetite, venous congestion, and raised blood pressure (1 patient each). 33 patients left the study. Serum FSH and LH levels were studied in 3 patients, vaginal smears in 38 patients, cervical mucus in 10 patients, and endometrial biopsy in 9 patients. Hepatic function was not affected in the 10 patients studied.
 ...
PMID:[Clinical and laboratory evaluation of prolonged administration of microdoses of d-Norgestrel]. 446 47

An approach to the management of the climacteric and postmenopausal patient is outlined. Menopause refers to the time at which menstruation ceases; climacteric, the period of transition. Neither is pathological. After the functional life of the ovary terminates when the supply of primary oocytes is exhausted, the feedback mechanism with FSH is disrupted leading to high blood and urinary levels of FSH. Estrogen often continues to be produced for about 10 years postmenopausally. Hormone therapy is indicated to treat vasomotor instability, such as hot flashes, numbness and tingling, vertigo, cold hands and feet, palpitations and headache, dysfunctional uterine bleeding, and senile vaginitis. The psychological changes often noted are functional and not due to estrogen withdrawal. There is currently no proof of the efficacy of long term estrogen replacement as a means of preventing heart diseases or osteoporosis.
 ...
PMID:Management of the climacteric and postmenopausal woman. 503 99

A group of 78 women with sudden flushes and associated disorders (pruritus vulvae, headache, anxiety, instability, depression, libido disturbances) related to the menopause were treated with one or two capsules of veralipride daily for 20 days. Excellent or good results were obtained in 54 of the 69 patients (78 p. cent) with sudden flushes, and 29 of the 57 cases (51 p. cent) with associated disorders. The difference in scores before and after treatment is very highly significant (p < 0.001). Clinical tolerance was good as only 2 cases of minimal galactorrhea. 2 cases of mastodynia, 3 cases with mild drowsiness, 2 patients with nervous tension or insomnia, 3 with digestive disorders, 1 with vertigo, and 1 with mild visual disturbances were observed. No modifications in the biological parameters studied were noted. Blood prolactin levels increased during treatment but returned to normal levels 4 days after discontinuation of therapy. No significant modifications in FSH, LH, E2, or E3 plasma levels were noted at the end of the study. Veralipride appears, therefore, to be the prototype for non-hormonal therapy of menopausal disorders.
 ...
PMID:[A new therapeutic approach to menopausal sudden flushes and psychofunctional disorders (author's transl)]. 625 60


<< Previous 1 2 3 4 5 6 Next >>